



மத்திய சித்த மருத்துவ ஆராய்ச்சிக் குழுமம்

ஆயுஷ் அமைச்சகம், இந்திய அரசு, அரும்பாக்கம்,
சென்னை-106

केंद्रीय सिद्ध अनुसन्धान परिषद्

आयुष मंत्रालयभारत सरकार ,

सिद्ध केंद्रीय अनुसन्धान संस्थान भवनचेन्नेई , अरुम्बाक्कम , अण्णा सरकारी अस्पताल परिसर , - 600106

CENTRAL COUNCIL FOR RESEARCH IN SIDDHA

Ministry of AYUSH, Govt. of India

SCRI Building, Anna Govt. Hospital Campus, Arumbakkam, Chennai – 600106

Phone: 2621 1621, 2621 2421 Fax: 044-2621 1621

www.siddhacouncil.com, www.siddharesearchcouncil.org, Email: ccrschennai@gmail.com

F.No. 1-15/2013/ CCRS /Tech. / Hqrs/

2nd April 2020

ACTIVITIES OF CCRS TO COMBAT COVID-19

1. An expert meeting for advocacy of Siddha in the Prevention and Management of Novel Corona Virus nCoV-2019 was held on 4th February 2020 at 11.30 am in the Mini-conference Hall (Ground floor) of the Siddha Central Research Institute (SCRI), CCRS, Chennai. Prof. Dr. K. Kanakavalli, Director General, CCRS, Chennai chaired the meeting. Prof. Dr. R. Meenakumari, Director, National Institute of Siddha, Chennai, Prof. Dr. P. Parthiban, Joint Director, Directorate of Indian Medicine & Homeopathy, Chennai, Prof. Dr. P. Jeyaprakash Narayanan, Chairman, SPC, Prof. Dr. G. Ganapathy, GB Member, CCRS. Dr. M. Pitchiah Kumar, State Licensing Authority, Government of Tamilnadu, Chennai & Dr. P. Sathiyarajeswaran, Assistant Director (Siddha), S-III &i/c, SCRI, Chennai were some of important members who took part in the meeting.
2. The minutes of meeting for Advocacy of Siddha in the Prevention and Management of Novel Corona Virus nCoV-2019 was prepared on 6th February 2020 and was circulated to the members on 7th February 2020.
3. Based on the aforesaid meeting an advisory entitled “Corona Virus: Preventive and Prophylactic Advocacy in Siddha System” was prepared providing the scope of research in Siddha system of medicine was submitted to Ministry of AYUSH on 12th February 2020.
4. A meeting was organised by Vaidya Rajesh Kotecha, Secretary, Ministry for AYUSH for framing the AYUSH advisory to combat COVID 19 at AYUSH Bhavan on 5th March 2020. Various officials from CCRAS, CCRUM, CCRH, CCRS, CCRYN, AIIA attended the meeting. Secretary AYUSH constituted a committee with respect to each AYUSH system for framing the advisory with herbal ingredients only on the same day comprising Dr. Azim Ali Khan, CCRUM, Dr. N. Srikanth, CCRAS, Dr. Naik, Dr. Raghavendra Rao, CCRYN and Dr. R. Manickavasagam, CCRS. The draft was prepared based on the research articles already published and proposal given by the President TANSOMA to Secretary AYUSH. The list of medicines was finalized with the help of supporting documents--- clinical, pre-clinical, review articles which was

submitted to the committee. Nilavembu kudineer consumption details at SCRU New Delhi was also provided as per the suggestions of DG, CCRS. The Advisory was then approved by the Vaidya Rajesh Kotecha, Secretary, Ministry for AYUSH which was also presented by the Secretary to the Parliamentary team.

5. Based on the Advisory submitted by CCRS and the meeting held on 5th March 2020 at AYUSH Bhawan, Vaidya Rajesh Kotecha Ji, Secretary, Ministry of AYUSH issued an Advisory vide letter dated 6th March 2020 (Reference: D. O. No. S. 16030/18/2019 – NAM) from Ministry of AYUSH for meeting the Challenge Arising out of spread of Corona Virus (COVID-19) in India.
6. A Covid Information Cell was created by the Ministry of AYUSH on 24th March 2020. The number of beds available for quarantine at peripheral Institutes of CCRS was provided. The details were also entered in the online portal covid19.nhp.gov.in.
7. Prof. Dr. K. Kanakavalli, Director General, Central Council for Research in Siddha (CCRS), Chennai along with Siddha experts Prof. P. Jeyaprakash Narayanan, Former Principal, Government Siddha Medical College, Chennai & Chairman, SPC/ SAC, NIS, Dr. M. Pitchiahkumar, President, TANSMOA & The State Licensing Authority (Indian Medicine), and Dr. G. Sivaraman, Managing Director, Arogya Health Care Pvt. Ltd. interacted with Hon'ble Prime Minister Shri Narendra Modi pertaining to Siddha intervention for COVID-19 on 28th March 2020 (Saturday) at 10.00 a.m. at CCRS headquarters office, Arumbakkam, Chennai. On behalf of the expert team, Prof. P. Jeyaprakash Narayanan interacted with Hon'ble Prime Minister and advocated Nilavembu Kudineer and Kabha Sura Kudineer for the enhancing the immunity of the individual as well as for the prevention/prophylaxis of Covid -19.
8. A meeting was held under the Chairmanship of Shri. S. Ganesh, Director, Directorate of Indian Medicine and Homoeopathy (DIM& H) on 30th March 2020 at DIM&H. Prof. Dr. P. Parthibhan, Joint Director (Siddha), DIM& H, Prof. Dr. K. Kanakavalli, Director General, CCRS, Prof. R. Meenakumari, Director, NIS, Dr. M. Pitchiahkumar, The State Licensing Authority (Indian Medicine), Dr. Manavalan, Joint Director (Yoga and Naturopathy), Principal, GUMC and other experts participated in the meeting. The following suggestions was given by DG, CCRS in the meeting:
 - Nilavembu Kudineer was suggested as a preventive measure.
 - For symptom management of COVID -19 like illnesses, Kaba Sura Kudineer and Adathodai Manapagu were suggested.
 - Kaba Sura Kudineer can also be used as an add on Intervention to the Conventional Care.All these medicines should be taken in consultation with qualified physician of Siddha system of Medicine.
9. Prof. Dr. K. Kanakavalli, Director General, CCRS, participated in the meeting held on 30th March 2020 from 9.30 pm to 12 pm with Commerce Minister and Secretary, Ministry of AYUSH to receive the views of industrialists to tackle the Covid-19.
10. A letter seeking approval from the Ministry of AYUSH was submitted to carry out the in-vitro studies and Pre-clinical safety studies of Siddha formulations for Covid-19 in collaboration with International Centre for Genetic Engineering and Biotechnology, New Delhi and Sri Ramachandra Deemed University, Chennai.

11. CCRS has prepared a protocol entitled “Siddha Treatment Guidelines for COVID -19”.
12. CCRS has prepared a questionnaire for people providing essential service who are at high risk and isolated quarantined individuals to generate data on the use of NVK & KSK.